Alterity Therapeutics Operating Income Over Time
| ATHE Stock | USD 3.30 0.07 2.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alterity Therapeutics Performance and Alterity Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Alterity diversify its offerings? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alterity Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth 0.809 | Return On Assets | Return On Equity |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Alterity Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alterity Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alterity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Alterity Therapeutics and related stocks such as Dyadic International, Evaxion Biotech AS, and NanoViricides Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DYAI | (190.8 K) | 1.6 M | 1.6 M | 556.5 K | (5.3 M) | (3.6 M) | (6 M) | (7.1 M) | (7.6 M) | (9.3 M) | (10 M) | (14.7 M) | (10.2 M) | (8.2 M) | (5.9 M) | (5.3 M) | (5.6 M) |
| EVAX | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (11.4 M) | (16.6 M) | (25.8 M) | (25.3 M) | (22.2 M) | (14.7 M) | (13.3 M) | (13.9 M) |
| NNVC | (66 K) | (6.1 M) | (6.6 M) | (8.7 M) | (7.1 M) | (8.9 M) | (9.6 M) | (9.3 M) | (8.7 M) | (8 M) | (8.7 M) | (8.1 M) | (8.9 M) | (8.5 M) | (9.6 M) | (8.6 M) | (9.1 M) |
| LIMN | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.7 M) | (2.6 M) | (2.9 M) | (2.6 M) | (2.7 M) |
| IGC | 136.9 K | (7.5 M) | (2.5 M) | (2.5 M) | (4.3 M) | (2.9 M) | (2.1 M) | (1.8 M) | (4.6 M) | (6.9 M) | (8.7 M) | (15.4 M) | (11.6 M) | (9.8 M) | (7.4 M) | (6.7 M) | (7 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (20 M) | (33.6 M) | (82.3 M) | (106.9 M) | (159.6 M) | (171.8 M) | (67.2 M) | (60.5 M) | (63.5 M) |
| ANVS | (354.9 K) | (1.8 M) | (1.8 M) | (682.4 K) | (682.4 K) | (682.4 K) | (682.4 K) | (682.4 K) | (713.9 K) | (1.6 M) | (6.6 M) | (14.5 M) | (25.5 M) | (45 M) | (26.7 M) | (24 M) | (22.8 M) |
| MAIA | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (7 M) | (7.8 M) | (16.2 M) | (20.2 M) | (17 M) | (15.3 M) | (16 M) |
| GBIO | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (62.3 M) | (81.1 M) | (119.1 M) | (141.2 M) | (138.6 M) | (142.4 M) | (128.2 M) | (134.6 M) |
Alterity Therapeutics and related stocks such as Dyadic International, Evaxion Biotech AS, and NanoViricides Operating Income description
Operating Income is the amount of profit realized from Alterity Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Alterity Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Alterity Therapeutics | ATHE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 350 Collins Street, |
| Exchange | NASDAQ Exchange |
USD 3.3
Check out Alterity Therapeutics Performance and Alterity Therapeutics Correlation. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Alterity Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.